Literature DB >> 16580609

Nephrogenic diabetes insipidus.

Daniel G Bichet1.   

Abstract

Nephrogenic diabetes insipidus (NDI), which can be inherited or acquired, is characterized by an inability to concentrate urine despite normal or elevated plasma concentrations of the antidiuretic hormone arginine vasopressin (AVP). Polyuria, with hyposthenuria, and polydipsia are the cardinal clinical manifestations of the disease. About 90% of patients with congenital NDI are males with X-linked recessive NDI (OMIM 304800) who have mutations in the arginine-vasopressin receptor 2 (AVPR2) gene that codes for the vasopressin V2 receptor. In about 10% of the families studied, congenital NDI has an autosomal recessive or autosomal dominant mode of inheritance (OMIM 222000 and 125800). In these families, mutations have been identified in the aquaporin-2 gene (AQP2) (OMIM 107777), which codes for the vasopressin-sensitive water channel. Most missense AVPR2 mutations lead to receptors that are trapped intracellularly; a few mutant receptors reach the cell surface but are unable to bind AVP or to properly trigger an intracellular cyclic adenosine monophosphate signal. Similarly, most AQP2 mutant proteins are also misrouted. Prior knowledge of AVPR2 or AQP2 mutations in NDI families and perinatal mutation testing is of direct clinical value because early diagnosis and treatment can avert the physical and mental retardation associated with repeated episodes of dehydration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16580609     DOI: 10.1053/j.ackd.2006.01.006

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  38 in total

1.  V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.

Authors:  Kazuhiro Takahashi; Noriko Makita; Katsunori Manaka; Masataka Hisano; Yuko Akioka; Kenichiro Miura; Noriyuki Takubo; Atsuko Iida; Norishi Ueda; Makiko Hashimoto; Toshiro Fujita; Takashi Igarashi; Takashi Sekine; Taroh Iiri
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

Review 2.  Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.

Authors:  Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2011-01

3.  Rescue of misrouted GnRHR mutants reveals its constitutive activity.

Authors:  Jo Ann Janovick; Irina D Pogozheva; Henry I Mosberg; Anda Cornea; P Michael Conn
Journal:  Mol Endocrinol       Date:  2012-05-17

Review 4.  Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease.

Authors:  P Michael Conn; Jo Ann Janovick
Journal:  Mol Cell Endocrinol       Date:  2008-11-18       Impact factor: 4.102

5.  The constitutively active V2 receptor mutants conferring NSIAD are weakly sensitive to agonist and antagonist regulation.

Authors:  Julie Tenenbaum; Mohammed A Ayoub; Sanja Perkovska; Anne-Laure Adra-Delenne; Christiane Mendre; Bruno Ranchin; Giamperro Bricca; Ghislaine Geelen; Bernard Mouillac; Thierry Durroux; Denis Morin
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

Review 6.  Assay strategies for identification of therapeutic leads that target protein trafficking.

Authors:  P Michael Conn; Timothy P Spicer; Louis Scampavia; Jo Ann Janovick
Journal:  Trends Pharmacol Sci       Date:  2015-06-08       Impact factor: 14.819

Review 7.  Familial forms of diabetes insipidus: clinical and molecular characteristics.

Authors:  Muriel Babey; Peter Kopp; Gary L Robertson
Journal:  Nat Rev Endocrinol       Date:  2011-07-05       Impact factor: 43.330

8.  Novel activators of aquaporin 2 membrane expression for the treatment of nephrogenic diabetes insipidus: less is more. Focus on "High-throughput chemical screening identifies AG-490 as a stimulator of aquaporin 2 membrane expression and urine concentration".

Authors:  Jeff M Sands; Mitsi A Blount
Journal:  Am J Physiol Cell Physiol       Date:  2014-06-18       Impact factor: 4.249

Review 9.  Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs.

Authors:  P Michael Conn; Alfredo Ulloa-Aguirre
Journal:  Trends Endocrinol Metab       Date:  2009-12-11       Impact factor: 12.015

Review 10.  Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.

Authors:  Chaya G Bhuvaneswar; Ross J Baldessarini; Veronica L Harsh; Jonathan E Alpert
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.